07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Feburic febuxostat regulatory update

Teijin said Japan approved an expanded label for Feburic febuxostat to include treatment of hyperuricemia caused by chemotherapy. The non-purine selective inhibitor of xanthine oxidase is approved in Japan for hyperuricemia with or without...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

AC-201 CR: Interim Phase IIa data

Interim data from 36 gout patients in the first cohort of the double-blind, Taiwanese Phase IIa AC-201-GOU-002 trial showed that twice-daily oral AC-201 CR met the criteria of >=2 more responders, defined as achieving a...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

Zurampic lesinurad: Additional Phase III data

AstraZeneca reported additional data from the double-blind, placebo-controlled, international Phase III CRYSTAL trial of lesinurad in 324 gout patients with tophi (visible nodules of uric acid crystals that are deposited in joints and skin). In...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Febuxostat regulatory update

The European Commission approved an expanded label for Adenuric febuxostat from Menarini to include the prevention and treatment of hyperuricemia in adults undergoing chemotherapy for hematologic malignancies at intermediate- to high-risk of tumor lysis syndrome....
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Lesinurad: Additional Phase III data

Additional data from the double-blind, placebo-controlled, international Phase III CRYSTAL trial in 324 gout patients with tophi (visible nodules of uric acid crystals that are deposited in joints and skin) showed that 76.1% of patients...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Adenuric febuxostat regulatory update

EMA’s CHMP recommended approval of an expanded label for Adenuric febuxostat from Menarini to include prevention and treatment of hyperuricemia in adults undergoing chemotherapy for hematologic malignancies at intermediate to high risk of tumor lysis...
03:03 , Feb 25, 2015 |  BC Extra  |  Clinical News

CymaBay falls on Phase IIb gout data

CymaBay Therapeutics Inc. (NASDAQ:CBAY) fell $2.27 (19%) to $9.98 on Tuesday after reporting interim data from its Phase IIb trial of arhalofenate ( MBX-102) to treat gout. While the trial met its primary endpoint --...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

Arhalofenate: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 32 patients with gout showed that 7%, 43% (p<0.05) and 79% of patients receiving once-daily 600 mg oral arhalofenate plus 40 mg febuxostat and 20%,...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AC-201: Phase II started

TWi began a double-blind, international Phase II trial to compare 100 mg oral AC-201 twice daily for 12 weeks plus febuxostat vs. placebo plus febuxostat in about 140 patients. TWi Pharmaceuticals Holding Inc. (GreTai:4180), Taipei,...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Lesinurad: Phase III data

Top-line data from the double-blind, placebo-controlled, international Phase III CRYSTAL trial in 324 gout patients with tophi (visible nodules of uric acid crystals that are deposited in joints and skin) showed that once-daily 400 mg...